BAVA:VIE
Bavarian Nordic A/S
€32.24
arrow_upward
+1.00%(+0.32) 1D
Okt 16, 11:00:18 AM GMT+2 · EUR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa BAVA...
Buksan
€31.94
Mataas
€32.24
Mababa
€31.94
Mkt. cap
2.83B
Avg. na dami
17.00
Dami
0.00
Mataas nang 52-wk
€32.47
Mababa nang 52-wk
€22.96
Bilang ng mga empleyado
2K
Buksan
€31.94
Mataas
€32.24
Mababa
€31.94
Mkt. cap
2.83B
Avg. na dami
17.00
Dami
0.00
Mataas nang 52-wk
€32.47
Mababa nang 52-wk
€22.96
Bilang ng mga empleyado
2K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Reuters
·
10 oras ang nakalipas
S&P 500 ends higher as traders shift from AI to healthcare
MarketWatch
·
1 buwan ang nakalipas
The S&P 500 keeps climbing on days when stocks broadly struggle. Here’s what’s going on.
The Motley Fool
·
5 araw ang nakalipas
VOO Doesn't Hold SpaceX, Taiwan Semiconductor, Samsung Electronics, SK Hynix, or ASML. Meet the Vanguard ETF That Does.
New York Post
·
3 araw ang nakalipas
Wall Street’s big but narrow rally: 4 in 10 S&P stocks are down this year
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Tungkol sa Bavarian Nordic A/S